Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

Navrogen, Inc. has announced groundbreaking advancements in monoclonal antibody (mAb) and antibody-drug conjugate (ADC) ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs ...

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...